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A Novel Immunoglobulin Superfamily Receptor
for Cellular and Viral MHC Class I Molecules
David Cosman, Neil Fanger, Luis Borges, class I heavy chain for b2m binding. However, a virus
from which the UL18 gene was deleted was unimpairedMarek Kubin, Wilson Chin, Lori Peterson,
and Mei-Ling Hsu for host class I down-regulation (Browne et al., 1992).
Subsequently, the CMV US2, US3, and US11 gene prod-Immunex Corporation
51 University Street ucts have been shown to be responsible for this phe-
nomenon (Jones et al., 1995; Ahn et al., 1996; Jones etSeattle, Washington 98101
al., 1996; Wiertz et al., 1996).
More recently, it has been postulated that UL18 may
play a role in the protection of virus-infected cellsSummary
against cytotoxicity mediated by natural killer (NK) cells
(Fahnestock et al., 1995). NK cell cytotoxicity is triggeredThe human cytomegalovirus UL18 gene product is a
by the absence or alteration of MHC class I moleculeshomolog of cellular major histocompatibility (MHC)
on the target cell, termed the ªmissing selfº hypothesisclass I antigens. UL18 has been proposed to protect
(Ljunggren and Karre, 1990). NK cells possess receptorsvirus-infected cells against natural killer (NK) cell cyto-
for MHC class I molecules, known as killer inhibitorytoxicity by engaging NK cell killer inhibitory receptors
receptors (KIR) (reviewed by Moretta et al., 1996; Mo-(KIR) for MHC class I. UL18 binds to a novel immuno-
retta et al., 1997). These receptors are members of theglobulin superfamily glycoprotein, designated Leuko-
immunoglobulin or C-type lectin superfamilies and,cyte Immunoglobulin-like Receptor (LIR-1). This pro-
upon engagement by MHC class I, transmit an inhibitorytein is distinct from, but related to, known KIRs and
signal to the NK cell cytolytic machinery, preventingbinds cellular MHC class I antigens. The cytoplasmic
target cell lysis. The inhibitory signal is believed to bedomain of LIR-1 contains four putative immunorecep-
mediated in part by the binding of the Src homologytor tyrosine-based inhibitory motifs. Upon tyrosine
domain±containing tyrosine phosphatase (SHP-1) tophosphorylation, LIR-1 associates with the tyrosine
phosphorylated immunoreceptor tyrosine-based inhibi-phosphatase SHP-1. In contrast to KIRs, LIR-1 is ex-
tory motifs (ITIMs) in the cytoplasmic domains of thepressed predominantly on monocytic and B lymphoid
KIRs and subsequent dephosphorylation of signalingcell types, suggesting a distinct biological function.
molecules essential for NK cytolytic activation (Bin-
stadt et al., 1996; Burshtyn et al., 1996; Campbell et al.,Introduction
1996; Fry et al., 1996; Olcese et al., 1996). SHP-1 has
also been implicated as an important negative regulatorThe battlefield of virus±immune system interactions
of signaling through several cytokine receptors, the Bprovides fertile ground for studying the molecular
cell coreceptor, CD22, and the inhibitory Fc receptor,mechanisms of immune evasion and virus-induced im-
FcgRIIB (reviewed by Tonks and Neel, 1996). While pro-munopathology. Recently identified virus-encoded im-
tecting the cells from cytotoxic T cell surveillance, CMV-munomodulators include cytokines, soluble cytokine re-
induced down-regulation of host class I molecules theo-ceptors, Fc receptors, inhibitors of the complement
retically should leave the cells vulnerable to killing bypathway, and inhibitors of apoptosis (reviewed by
NK cells. Therefore, it has beensuggested that the CMV-Spriggs, 1996). Several viruses also target the major
encoded MHC class I±like molecule, UL18, might takehistocompatibility antigens of the host directly or indi-
the place of host MHC class I antigens on the cell sur-rectly. For example, the herpes simplex virus 1 ICP-47
face, engage the NK KIRs, and prevent NK-mediatedgene product inhibits the transport of peptides into the
cytotoxicity (Fahnestock et al., 1995).endoplasmic reticulum by the TAP protein (transporter
To test the hypothesis that UL18 binds to KIRs, aassociated with antigen processing) (York et al., 1994;
soluble UL18 fusion protein was constructed and shownHill et al., 1995). Peptide transport is essential for the
to bind to a cellular glycoprotein with a molecular weightsubsequent presentation of the peptides by major histo-
distinct from known KIRs. Expression cloning of thiscompatibility (MHC) class I molecules to cytotoxic T
UL18 counterstructure revealed it to be a member ofcells. It has long been known that human cytomegalovi-
the immunoglobulin superfamily, to contain four cyto-rus (CMV) infection results indown-regulation of expres-
plasmic ITIM-like motifs, and to be related to the KIRsion of host MHC class I antigens in order to protect
family and to several other immunoreceptors. Like KIRs,virus-infected cells from attack by class I±restricted,
the novel protein binds to cellular MHC class I antigens.cytotoxic T cells (Barnes and Grundy, 1992; Beersma
However, in contrast to KIRs, its predominant expres-et al., 1993; Yamashita et al., 1993).
sion is restricted to monocytes and B cells, suggestingCMV itself encodes an MHC class I±related protein,
a distinct but specific biological function.the UL18 gene product (Beck and Barrell, 1988). As with
host MHC class I molecules, this protein has beenshown
to bind b2-microglobulin (b2m) (Browne et al., 1990) and Results
endogenous peptides (Fahnestock et al., 1995). The bio-
logical role of UL18 remains enigmatic. Initially, It was Identification of a UL18-Binding Protein
A fusion protein containing the extracellular domain ofhypothesized that UL18 might be involved in host MHC
class I down-regulation by competing with the MHC UL18 and the Fc region of human immunoglobulin G1
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predicted to be that of a type 1 membrane glycoprotein
with an N-terminal signal sequence of 16 amino acids;
an extracellular region of 442 amino acids, which in-
cludes four potential N-linked glycosylation sites; four
immunoglobulin-like domains and a short ªspacerº re-
gion rich in serine and threonine residues that are likely
sites of O-linked glycosylation; a 25±amino acid hy-
drophobic transmembrane domain; and a 167±amino
acid cytoplasmic domain. Within the cytoplasmic do-
main are two pairs of putative ITIM-like motifs (N/V/
SxYxxL/Vx25±26YxxL/V). Immunoglobulin-like KIRs con-
tain one pair of ITIM motifs with a similar spacing. We
propose to call this molecule Leukocyte Immunoglobu-
lin-like Receptor (LIR-1). The amino acid sequence ofFigure 1. UL18-Fc Association with b2m
LIR-1 is related to the KIR family, the gp49 proteinsThe UL18-Fc protein, purified from transfected cells, was electro-
found on murine mast cells and NK cells (Castells et al.,phoresed under reducing conditions and visualized by Coomassie
blue staining. The positions of molecular weight standards (in kilo- 1994; Rojo et al., 1997; Wang et al., 1997), the bovine
daltons) are indicated. The identity of the 12 kDa band was verified neutrophil Fc receptor for IgG2 (Zhang et al., 1995), the
as simian b2m by direct amino acid sequencing. human IgA Fc receptor (Maliszewski et al., 1990), and
a recently described murine macrophage glycoprotein,
p91 (Hayami et al., 1997). However, the combination of
(IgG1) was constructed. Upon expression in CV-1/EBNA four immunoglobulin domains and four ITIM-like motifs
monkey kidney cells, the UL18-Fc protein was secreted is found only in LIR-1 (Figure 4B).
in association with monkey b2m (Figure 1). Under reduc- Upon transfection of LIR-1 cDNA into COS-1 cells, a
ing conditions UL18-Fc has an apparent molecular UL18-Fc binding protein of 110±120 kDa was detected
weight of 100±115 kDa and, as with other Fc fusion that was not seen in cells transfected with the vector
proteins, UL18-Fc is a disulfide-bonded dimer (data not alone or in lysates precipitated with an irrelevant Fc
shown). Using flow cytometry, the purified UL18-Fc pro- fusion protein (Figure 3B). This protein band was indis-
tein was tested for binding to a panel of primary cells tinguishable in size from that detected in CB23 cells
and cell lines. UL18-Fc showed specific binding to a (Figure 3A).
subpopulation of short-term cultured NK cells (Figure Since LIR-1 has some homology to Fc receptors, it
2A). The proportion of NK cells that bound to UL18-Fc was necessary to rule out the possibility that LIR-1 was
varied from 3% to 33% using cells from 17 different binding to the Fc portion of the UL18-Fc fusion protein.
donors (data not shown). Greater and more uniform A fusion protein was constructed between the LIR-1
binding was seen to a number of cell lines, including extracellular domain and IgG1 Fc. The LIR-1-Fc protein
CB23, U937, and Daudi (Figure 2B). The UL18-Fc protein had a subunit molecular weight of 130 kDa when ex-
was also used to precipitate a protein of 110±120 kDa pressed in COS-1 cells (data not shown). The LIR-1-Fc
from lysates of cell surface±biotinylated CB23 cells. A protein was then bound to CV-1/EBNA cells transfected
band of this size was not seen in lysates precipitated with full-length UL18 cDNA. Binding was detected by
with an irrelevant Fc fusion protein (Figure 3A). A protein the sensitive autoradiographic technique used for ex-
band of similar size was also detected in U937, THP-1, pression cloning. Clearly detectable and specific bind-
Daudi, Raji, and MP-1 cell lines and in primary mono- ing of LIR-1-Fc to UL18-transfected cells was seen (data
cytes (data not shown). This molecular weight is distinct not shown), indicating that the interaction of UL18 and
from that of any of the known KIRs (reviewed by Moretta LIR-1 is mediated by their extracellular domains.
et al., 1996, 1997).
Expression Cloning of a UL18 Counterstructure LIR-1 Is Expressed Predominantly
on B Cells and MonocytesTo characterize the UL18-Fc counterstructure, a cDNA
library constructed from the CB23 cell line was screened A monoclonal antibody was raised against LIR-1. Like
UL18-Fc, this antibody immunoprecipitated a 110±120for UL18-Fc binding by the direct expression of pools
of cDNA clones in CV-1/EBNA cells (McMahan et al., kDa protein from LIR-1±transfected COS-1 cells or from
CB23 cells. This band was not seen using an isotype-1991). Two positive pools were identified that, upon
breakdown to single cDNAs, gave rise to two very highly matched control antibody (Figures 3A and 3B). Flow
cytometry, using this antibody to stain freshly isolatedrelated sequences (Figure 4A). The two cDNA clones,
P3G2 and 18A3, are predicted to encode proteins of 650 peripheral blood mononuclear cells, demonstrated ex-
pression of LIR-1 on all CD141 monocytes and CD191and 652 amino acids, respectively. The two predicted
amino acid sequences are 99.4% identical, suggesting B cells. (Figure 5A). The highest expression of LIR-1 was
seen on a subset of monocytes that stained brightly forthat they are allelic variants of the same gene, although
the existence of two almost identical genes is also pos- CD16 and less brightly for CD14 and CD64 (data not
shown). The LIR-1 antibody showed weak to undetect-sible.
It is noteworthy that 18A3 lacks a potential N-linked able staining of CD31 T cells and CD561 NK cells (Figure
5A). Although the expression levels varied slightly, thisglycosylation site found in P3G2 at position 142. The
amino acid sequence encoded by the P3G2 cDNA is pattern of expression of LIR-1 was seen on cells from
A Receptor for Cellular and Viral MHC Class I
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Figure 2. UL18-Fc Binding to a Cellular Counterstructure
The indicated cells and cell lines were analyzed by flow cytometry.
(A) Short-term cultured CD561 CD161 NK cells stained with UL18-Fc
(10 mg/ml, shaded profile) or a control Fc fusion protein (open profile)
followed by PE-conjugated goat anti-human immunoglobulin.
(B) CB23, U-937, and Daudi cells stained with UL18-Fc (5 mg/ml,
filled profile) or heat-aggregated human IgG1 (open profile) followed
by biotin-conjugated, Fc-specific, mouse anti-human IgG and strep-
tavidin±PE.
10 individual donors. The previously observed binding bound strongly with LIR-1-Fc, including HSB-2, CB23,
U937, primary T, B, and NK cells (data not shown). Toof UL18-Fc to a subpopulation of short-term cultured
NK cells was completely blocked by a monoclonal anti- characterize theLIR-1 counterstructure, a cDNA expres-
sion library from HSB-2 (a T lymphoblastic leukemia cellbody to LIR-1 but not by a control antibody or an anti-
body to CD16 (Figure 5B). line) was screened for LIR-1-Fc binding. Two positive
cDNA pools were obtained, which upon breakdown
yielded two separate cDNA clones encoding the MHCLIR-1 Binds to Cellular MHC Class I Antigens
On the presumption that LIR-1 has a cellular counter- class I human leukocyte antigen A2 (HLA-A2) and HLA-
B44 molecules. As further evidence that the binding ofstructure, the binding of LIR-1-Fc to cells was examined
by flow cytometry. Many different cells and cell lines LIR-1-Fc to cells is mediated by MHC class I molecules,
Figure 3. Cell Surface Expression of Natural
and Recombinant LIR-1
Cell surface proteins from CB23 cells (A) or
transfected COS-1 cells (B) were biotinylated;
extracted; precipitated with UL18-Fc, with a
control Fc fusion protein, a monoclonal anti-
body directed against LIR-1, or with an iso-
type-matched control monoclonal antibody;
and electrophoresed under reducing condi-
tions. Biotinylated proteins were transferred
to a nitrocellulose membrane and detected
by ECL. The positions of molecular weight
standards (in kilodaltons) are indicated.
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Figure 4. LIR-1 Sequence and Structure
(A) Alignment of the amino acid sequences
encoded by the LIR-1 cDNA clones 18A3 and
P3G2. Domains of the proteins are labeled
together with the following features: filled
boxes, cysteine residues found in conserved
positions within the four immunoglobulin-
like domains; dark-shaded boxes, potential
N-linked glycosylation sites; and light-shaded
boxes, ITIM-like motifs (N/V/SxYxxV/L). The
GenBank accession numbers for the se-
quences are AF009220 (for P3G2) and
AF009221 (for 18A3).
(B) Schematic representation of the struc-
tures of LIR-1 and related immunoreceptors.
Percentage amino acid identities were com-
puted using the BESTFIT program of the
Wisconsin Package, version 8, Genetics Com-
puter Group (Devereux et al., 1984) to gener-
ate pairwise alignments of the extracellular
domains (including signal peptides) of the in-
dicated molecules with the LIR-1 P3G2 cDNA
encoded peptide sequence. Approximate
values are shown for the KIR p70 and p58
molecules because these belong to highly re-
lated gene families. Mu, murine; Bo, bovine;
Hu, human.
binding to CB23 cells and peripheral blood T cells, stim- for all HLA-A, HLA-B, and HLA-C antigens (Figure 6). In
all cases tested, the binding of LIR-1-Fc was blocked byulated in a variety of ways, was tested in the presence
or absence of the monoclonal antibody W6/32, specific W6/32 but not by an isotype-matched control antibody.
A Receptor for Cellular and Viral MHC Class I
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Figure 5. Expression of LIR-1
(A) Two-color flow cytometric analysis of
LIR-1 expression on circulating blood mono-
cytes and B lymphocytes. Peripheral blood
mononuclear cells were isolated and stained
as described in Experimental Procedures.
Each dot plot represents 10,000 gated pe-
ripheral blood mononuclear cells.
(B) Blocking of binding of UL18-Fc to NK cells
by anti-LIR-1. Short-term cultured NK cells,
prepared as described in Experimental Pro-
cedures, were stained with UL18-Fc (10 mg/
ml) and monoclonal antibodies to LIR-1 or
CD16 or a control monoclonal antibody (100
mg/ml), followed by PE-conjugated, Fc-spe-
cific, F(ab9)2 goat anti-human IgG and fluores-
cein isothiocyanate±conjugated goat anti-
mouse immunoglobulin.
Similar blocking of LIR-1-Fc binding by W6/32 was seen control monoclonal antibody. Detection of the 110±120
kDa band was blocked by incubation of the antibodyon a number of other cell lines and primary cells (data
not shown). to LIR-1 with the soluble LIR-1-Fc protein, but not by
incubation with a control Fc fusion protein. The LIR-1
band was not seen in the absence of pervanadate treat-LIR-1 Associates with SHP-1
KIRs and several other cell surface glycoproteins with ment, confirming that tyrosine phosphorylation was es-
sential for the association of LIR-1 and SHP-1.cytoplasmic ITIM motifs have been shown to engage
the protein tyrosine phosphatase, SHP-1. To test if LIR-1
bound to SHP-1, CB23 cells were treated with sodium Discussion
pervanadate, an inhibitor of tyrosine phosphatases, to
increase the levels of tyrosine phosphorylation on LIR-1. The hypothesis that UL18 might engage the known NK
KIRs to inhibit NK lysis of CMV-infected cells, whileIndeed, LIR-1 became detectably tyrosine phosphory-
lated only after sodium pervanadate treatment (Figure attractive, may need to be expanded based on the re-
sults presented here. These results show that UL18-Fc7A). CB23 lysates were immunoprecipitated by antibody
to SHP-1 and then probed by Western blotting with binds strongly to B lymphoblastoid and monocytic cell
lines, which are not known to express KIRs, and precipi-antibody against LIR-1. As seen in Figure 7B, a protein
of 110±120 kDa, corresponding toLIR-1, could readily be tates a protein of 110±120 kDa from these cells, a molec-
ular weight distinct from known KIRs. Moreover, LIR-1,detected in anti-SHP-1 immunoprecipitates, but not in
immunoprecipitates generated with an isotype-matched a novel member of the immunoglobin superfamily, has
Immunity
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Figure 6. Binding of LIR-1-Fc to Cells Is Blocked by an Antibody to
MHC Class I
Peripheral blood T cells (PBT), unstimulated or stimulated with phy-
tohemagglutinin (PHA) or phorbol myristic acetate and ionomycin
(PMA/IONO) or a combination of the stimuli, were bound with LIR-
1-Fc (5 mg/ml) alone or in the presence of the mouse monoclonal
antibody (W6/32) or a control monoclonal antibody (anti-CD8 for
the T cells and anti-CD20 for CB23). The blocking antibodies were
used at a concentration of 20 mg/ml for the T cells and 50 mg/ml
for the CB23 cells. Binding of the Fc fusion protein was detected
using PE-conjugated Fc-specific mouse anti-human IgG. Mean fluo-
rescence intensity values were calculated after subtraction of back-
ground staining values obtained with heat-aggregated human IgG.
been identified as a UL18 counterstructure. LIR-1, like
KIRs, binds to cellular MHC class I molecules. The func-
Figure 7. Association of LIR-1 with the Tyrosine Phosphatase,tion of UL18 is presumably mediated either through
SHP-1LIR-1 on the surface of a leukocyte binding to UL18
(A) Western blot of anti-LIR-1 immunoprecipitates from CB23 cellson the surface of a virus-infected cell or through the
incubated in the presence or absence of sodium pervanadate. The
interaction of the two molecules expressed together in blot was probed with an anti-phosphotyrosine monoclonal antibody
a virus-infected cell. There are many possibilities as to (a-PY).
where this interaction might take place in vivo, since (B) Western blot of anti-SHP-1 or control monoclonal antibody im-
munoprecipitates from CB23 cells incubated in the presence orCMV can infect a wide variety of cell types (reviewed
absence of Na pervanadate. The blot was probed with anti-LIR-1by Plachter et al., 1996). NK cells have been shown to
polyclonal antiserum (lanes 1±4). The anti-LIR-1 antiserum was pre-play an important role in the early responses to murine
incubated with soluble LIR-Fc (lane 6) or a control Fc fusion protein
CMV (MCMV) infection, and patients with NK deficien- (lane 5) prior to probing of the blot. The positions of molecular weight
cies show increased susceptibility to herpesvirus infec- standards (in kilodaltons) are indicated.
tions (reviewed by Biron, 1997). A recent investigation
(Reyburn et al., 1997) demonstrated that introduction
of full-length UL18 into an MHC class I±negative, NK-
Alternatively, the high-level expression of LIR-1 onsensitive cell line protected the cells from NK cytotoxic-
monocytes might suggest a role for UL18 in limiting anti-ity. This protection was reversed by an antibody against
viral effector functions of these cells, such as antibody-CD94, a KIR of the C-type lectin family (Chang et al.,
dependent cellular cytotoxicity, interferon production,1995) that is expressed on most NK cells (Aramburu et
or release of cytotoxic molecules like superoxide oral., 1990), suggesting a possible interaction between
nitric oxide. It is noteworthy that the subpopulation ofUL18 and CD94. However, in the current study, binding
monocytes showing the highest LIR-1 expression (CD642of UL18-Fc or anti-LIR-1 antibody to freshly isolated
CD16brightCD14dull [Figure 5 and data not shown]) hasCD561 NK cells was low to undetectable, and the low
been reported to be the major source of monocyte-binding of UL18-Fc to a subpopulation of cultured NK
derived interferon-a (Grage-Griebenow et al., 1993). In-cells was blocked by anti-LIR-1 (Figure 5). It is possible
terferon-a/b has been shown to be induced by MCMVthat a UL18-CD94 interaction might not have been de-
infection in vivo and to be required for MCMV-inducedtected by flow cytometry due to a low binding affinity
NK cell blastogenesis and cytotoxicity (Orange andor to the use of a UL18Fc fusion protein, which might
Biron, 1996). It has been shown recently that disruptionshow different binding properties from the membrane-
of the MCMV MHC class I±like gene, m144, results in abound form of the molecule. It is also possible that
decreased ability of the virus to control the antiviralbinding of UL18-Fc to CD94 or to other counterstruc-
activity of NK cells (Farrell et al., 1997). The action oftures on NK cells might be dependent on the state of
cell activation or restricted to NK cell subsets. m144 might be directly on NK cells or hypothetically via
A Receptor for Cellular and Viral MHC Class I
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inhibition of the production of monocyte-derived cyto- motheaten mouse (in which the SHP-1 gene is mutated)
provide some signposts for investigation (Shultz et al.,kines essential for NK function. CMV infects monocytes
and has been reported to inhibit hematopoietic pro- 1993; Tsui et al., 1993).
Finally, LIR-1 appears to be the prototype of a newgenitor function (MacKintosh et al., 1993; Movassagh
et al., 1996; Plachter et al., 1996; Sindre et al., 1996). It family of molecules. We have recently identified a num-
ber of novel LIR-1±related cDNAs that show greater ho-is possible, therefore, that engagement of monocyte
LIR-1 by UL18 might contribute to this effect. mology to LIR-1 than to KIRs or other immunoreceptors
(Borges et al., submitted). Very recently, Samaridis andLIR-1 is related to a number of immunoreceptors, with
closest homologies to KIRs, the IgA Fc receptor, the Colonna (1997) published the sequences of two new
members of the immunoglobulin superfamily, ILT1 andbovine neutrophil IgG2 Fc receptor, the mouse gp49
antigens, and themouse macrophage glycoprotein, p91. ILT2. ILT2 corresponds to LIR-1 and ILT1 to an LIR-1±
related cDNA that we have also isolated. These twoHowever, LIR-1 has a distinct structure with four extra-
cellular immunoglobulin domains and four cytoplasmic molecules, although highly related in their extracellular
domains, differ in their transmembrane and cytoplasmicITIM-like motifs. LIR-1 does share with KIRs the ability
to bind class I MHC antigens, whereas the ligands for domains. ILT2/LIR-1 has a fully hydrophobic transmem-
brane domain and an ITIM-containing cytoplasmic do-gp49 and p91 are not yet defined. Although the detailed
allelic and locus specificity of MHC class I antigen bind- main, whereas ILT1 and several members of our LIR-1±
related family have transmembrane domains that includeing to LIR-1 has yet to be defined, it is apparent from
data presented here that LIR-1 recognizes a broader a positively charged residue and short cytoplasmic do-
mains without ITIMs. The same paradigm is also seenrange of class Imolecules than the immunoglobulin fam-
ily KIRs. Individual KIRs are specific for certain alleles within the immunoglobulin-family KIRs in which the mol-
ecules lacking ITIMs are stimulatory rather than inhibi-of either HLA-A, HLA-B, or HLA-C, whereas LIR-1 at a
minimum binds to alleles of both HLA-A and HLA-B, as tory receptors for specific MHC class I alleles (Moretta
et al., 1995; Biassoni et al., 1996). A similar duality iswitnessed by expression cloning of HLA-A2 and HLA-
B44 cDNAsusing LIR-1-Fc. In addition, LIR-1-Fc binding observed within a new family of molecules belonging to
the immunoglobulin superfamily, the SIRPs, which wereto several primary cells and cell lines is blocked by
W6/32, a pan±anti-HLA-A, -B, -C monoclonal antibody, recently identified by their association with the SHP-2
tyrosine phosphatase (Kharitonenkov et al., 1997). Byindicating that LIR-1 binding is unlikely to be limited to
only one allele at each locus. It is noteworthy that CD94, analogy, LIR-1±related molecules without cytoplasmic
ITIMS would be expected to send an activation signala C-type lectin KIR, also shows a broad specificity of
MHC class I recognition (Phillips et al., 1996; Sivori et upon binding their counterstructures. The interplay of
positive and negative signaling mediated by these novelal., 1996).
Within the cytoplasmic domain of LIR-1 are four ITIM- families of immunoglobulin-like receptors is likely to be
of importance in the fine regulation of immune functionlike motifs. KIRs contain two similarly spaced ITIMs that
have been shown to bind the tyrosine phosphatase as well as in cellular functions outside the immune
system.SHP-1 and mediate the inhibitory function of KIRs. Two
ITIMs have also been found in the cytoplasmic domain In summary, the use of a putative immunomodulatory
viral glycoprotein has led to the identification of a novelof gp49B1, a molecule of unknown function found in
murine mast and NK cells (Castells et al., 1994; Rojo et immunoreceptor that binds MHC class I molecules and
is likely to mediate an inhibitory signal. Further study ofal., 1997; Wang et al., 1997). gp49B1 has also been
shown to mediate an inhibitory signal when co-cross- this protein and its relatives is likely to enhance under-
standing of new immunoregulatory pathways and of thelinked to the IgE Fc receptor on mast cells (Katz et al.,
1996), and the cytoplasmic domain of gp49B1, when interplay between viruses and the immune system.
fused to the extracellular domain of a KIR, can send an
Experimental Proceduresinhibitory signal to NK cells (Rojo et al., 1997). gp49B1
has been proposed as a possible murine equivalent of
DNA Libraries and Construction of Fusion Proteinshuman KIRs, but no data have been published on
A cDNA library was constructed from poly(A)1 RNA extracted from
gp49B1-MHC class I interactions. The cytoplasmic do- cycloheximide-treated human foreskin fibroblasts infected with hu-
main of p91, a mouse macrophage glycoprotein, con- man CMV, strain AD169, at 8 hr postinfection. Oligo(dT) primed
tains four ITIM-like motifs with similar sequence and cDNA was synthesized using the Time Saver cDNA synthesis kit
(Pharmacia), ligated to EcoRI adaptors, and inserted into the EcoRIspacing to those in LIR-1 (Hayami et al., 1997). However,
site of the l ZAPII vector (Stratagene). The library was packagedthe extracellular region of p91 contains six immunoglob-
using the MaxPlax packaging extract (Epicentre Technologies) andulin-like domains, so that it is unclear if p91 represents
plated on Escherichia coli strain XL-1-Blue MRF9 (Stratagene).
the murine homolog of LIR-1. We have shown that LIR-1 The cDNA libraries from the B lymphoblastoid line CB23 and the
can be inducibly tyrosine phosphorylated and that it T lymphoblastic leukemia cell line HSB-2 have been described pre-
interacts with SHP-1 in a tyrosine phosphorylation± viously (McMahan et al., 1991; Kozlosky et al., 1995).
The UL18 sequence was isolated from the CMV-infected fibroblastdependent manner in a B lymphoblastoid cell line. These
library by standard polymerase chain reaction using oligonucleo-data support the notion that LIR-1 is likely to send an
tides to amplify the whole coding region and to add NotI sites toinhibitory signal when it engages its counterstructures,
either end. The amplification product was digested with NotI and
UL18 or cellular MHC class I molecules. However, the cloned into the mammalian expression vector pDC409 (Giri et al.,
pathways affected by a LIR-1±mediated inhibitory signal 1994). To construct a UL18-Fc fusion protein, the extracellular do-
are not yet known. Assuming that this signal is mediated main of UL18, from amino acids 1±318 (Beck and Barrell, 1988), was
amplified using oligonucleotides to add a 59 SalI site and a 39 BglIIwholly or partly by SHP-1, the pleiotropic defects in the
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site as well as the first three amino acids (E-P-R) of the hinge region with streptavidin±horseradish peroxidase (Amersham) at room tem-
perature for 30 min, and washed. Biotinylated proteins were visual-of human IgG1 Fc. The amplification product was digested with SalI
and BglII and ligated together with a BglII±NotI fragment encoding ized by the ECL Western blotting detection reagents (Amersham).
a modifiedhuman IgG1 Fc region(Baum et al., 1994) into the pDC409
expression vector cut with SalI and NotI. The resulting plasmid was
Immunoprecipitation and Western Blottingcalled pDC409/UL18-Fc.
CB23 cells were pelleted by centrifugation, subdivided into twoTo construct a LIR-1-Fc fusion protein, the extracellular domain of
aliquots and either stimulated for 5 minutes with 50 mM sodiumLIR-1, aminoacids 1±461 from clone P3G2 (Figure4A), was amplified
pervanadate or left unstimulated. After stimulation, the cells wereusing oligonucleotides to add a 59 SalI site, 39 BglII site and a factor
immediately lysed in RIPAbuffer containing 1% NP-40,0.5% sodiumXa cleavage site (I-E-G-R). The amplified fragment was digested with
deoxycholate, 50 mM Tris (pH 8), 2 mM EDTA, 0.5 mM sodiumSalI and BglII, ligated to the IgG1 Fc fragment, and cloned into
orthovanadate, 5 mM sodium fluoride, 25 mM b-glycerol phosphate,pDC409 as described above.
and protease inhibitors. For each immunoprecipitation, 24 3 106Plasmids encoding UL18-Fc or LIR-1-Fc were transfected into
cell equivalents were incubated for 2 hr at 48C with either 5 mg/mlCV-1/EBNA (ATCC CRL-10478) or COS-1 (ATCC CRL-1650) cells,
of anti-SHP-1 antibody (Transduction Laboratories) or 5 mg/ml ofand the fusion proteins were purified from culture supernatants by
an isotype-matched antibody control (anti-Flag-M5 IgG1) or anti-chromatography on a protein A±Poros column (PerSeptive Biosys-
LIR-1 polyclonal antiserum at a 1:200 dilution. The immunocom-tems) as described (Fanslow et al., 1992).
plexes were precipitated by incubation with protein G±Agarose
(Boehringer Mannheim) or protein A±Sepharose (Pharmacia),
washed, and resuspended in 40 ml of 23 SDS-PAGE sample buffer.Expression Cloning
The procedures used were those previously described (McMahan Twenty microliters of each immunoprecipitate were loaded per gel,
electrophoresedunder reducing conditions, and transferred to nitro-et al., 1991; Goodwin et al., 1993). In brief, plasmid DNA from pools
of 1,000±4,000 cDNA clones were transfected into CV-1/EBNA cells cellulose membranes (Amersham). Western blots were probedeither
with anti-LIR-1 polyclonal antisera or with an anti-phosphotyrosinegrown on one-chambered glass slides. Two or 3 days after transfec-
tion, the cells were incubated with 1 mg/ml of UL18-Fc protein or antibody (PY-20, Transduction Laboratories). Immunocomplexes
were detected by enhanced chemiluminescence (New England Nu-0.45 mg/ml of LIR-1-Fc protein in binding buffer followed by 125I-Fc-
specific mouse anti-human IgG for 30 min at room temperature. The clear).
cells were washed, fixed, and processed for autoradiography as
previously described. Positive pools were subdivided until a single
Cell Lines and Purification of Cellsclone was obtained that conferred UL18-Fc or LIR-1-Fc binding.
CB23 is an EBV-transformed, B lymphoblastoid cell line (Benjamin
and Dower, 1990); Daudi is a Burkitt's lymphoma cell line (ATCC
CRL-213); and U-937 is a monocyte-like histiocytic lymphomaGeneration of Antibodies to LIR-1
BALB/c mice were immunized at 0, 2, and 6 weeks with 10 mg (ATCC CRL-1593). Peripheral blood T cells were prepared as de-
scribed (Yao et al., 1996) and stimulated for 24 hr with 1% PHA orof LIR-1-Fc. The primary immunization was prepared with Termax
adjuvant (Vaxcel, Norcross, VA), and subsequent immunizations 10 ng/ml PMA plus 500 ng/ml ionomycin or a combination of the
stimuli. Peripheral blood mononuclear cells were obtained fromwith incomplete Freund's adjuvant (Sigma). At 11 weeks, mice were
boosted intravenously with 3±4 mg of LIR-1-Fc in phosphate-buf- healthy donors using Histopaque 1077 (Sigma) according to the
manufacturer's instructions. Short-term cultured NK cells were ob-fered saline (PBS). Three days later, splenocytes were harvested
and fused with the Ag8.653 myeloma fusion partner (ATCC CRL- tained as described (Perussia et al., 1987) and purified by magnetic
negative selection using a MACS column (Miltenyi Biotec, Auburn,1580) using 50% PEG 1500 (Sigma). Hybridoma supernatants were
screened by enzyme-linked immunosorbent assay (ELISA) using CA) with a combination of anti-CD3, CD4, CD19, and CD33 antibod-
ies according to the manufacturer's directions. The resulting cellsLIR-1±transfected COS-1 cells (2 3 103 cells per well in PBS) and
dried to polystyrene 96-well microtiter plates as the platecoat anti- were greater than 95% CD32CD161CD561.
gen (Linbro, EIA plates). The ELISA was probed with goat anti-
mouse Fc-HRP (Jackson Immunoresearch), followed by TMB sub-
Flow Cytometric Analysisstrate (Kirkegaard and Perry Labs) and read at 650 nm wavelength.
The following monoclonal antibodies were used for flow cytometricPositive supernatants were subsequently confirmed by flow cy-
analysis: M2, IgG1 anti-FLAG isotype control (Immunex); MOPC-21,tometry and immunoprecipitation using LIR-1±transfected COS-1
nonspecific IgG1 isotype control; MOPC-173, nonspecific IgG2acells. Hybridomas were cloned and followed using the same assay.
isotype control; UCHT1, IgG2a anti-CD3; M5M2, IgG2a anti-CD14;Monoclonal cultures were expanded and monoclonal antibodies
B43, IgG1 anti-CD19; B159, IgG1 anti-CD56 (all purchased frompurified by protein A affinity chromatography (BioRad protein A
PharMingen); 3G8, IgG1 anti-CD16 (Caltag Laboratories); B73.1,agarose).
IgG1 anti-CD16 (a generous gift from G. Trinchieri); IgG2a anti-CD8Rabbit polyclonal antiserum was generated by immunization of a
(ATCC CRL-8014); IgG2a anti-CD20 (ATCC HB-9645); and W6/32,New Zealand White rabbit with 100 mg of LIR-1-Fc in Titermax adju-
IgG2a pan±anti-HLA-A, -B, -C (ATCC HB-95).vant followed, 4 weeks later, by one boost of 50 mg of protein in
Cells were incubated with Fc fusion proteins under conditionsincomplete Freund's adjuvant. The animal was exsanguinated at 22
previously shown to block nonspecific and Fc receptor-mediatedweeks.
binding (Baum et al., 1994; Yao et al., 1996). Specific binding was
detected with either biotin-conjugated, Fc-specific, mouse anti-
human IgG (Jackson Immunoresearch) followed by phycoerythrinCell Surface Biotinylation, Precipitation,
and Detection of Proteins (PE)±conjugated streptavidin (Molecular Probes), or by PE-conju-
gated, Fc-specific, mouse anti-human IgG (Jackson Immunore-Cell surface proteins were biotinylated as described (Meier et al.,
1992). After extensive washing, the cells were lysed in PBS con- search), or by affinity purified, PE-conjugated, Fc-specific, F(ab9)2
goat anti-human IgG (Jackson Immunoresearch). For two-colortaining 0.5% NP40 and a cocktail of protease inhibitors. Aliquots
of the lysate were incubated with 5 mg/ml of Fc fusion protein or analysis, cells were stained with PE-conjugated monoclonal anti-
bodies specific for CD3, CD14, CD16, CD19, and CD56 and biotin-monoclonal antibody overnight at 48C. Protein A±Sepharose was
added for an additional hour. Precipitates werecollected by centrifu- conjugated anti-LIR-1 monoclonal antibody in the presence of heat-
aggregated, pooled human serum, followed by APC-streptavidingation and washed five times in lysis buffer. Bound proteins were
eluted by boiling for 5 min in reducing SDS-polyacrylamide gel elec- (Molecular Probes). For costaining with Fc fusion proteins and
monoclonal antibodies, detection was with PE-conjugated, Fc-spe-trophoresis (SDS-PAGE) sample buffer and resolved by electropho-
resis on 4±20% polyacrylamide gels (Novex) using enhanced chemi- cific, F(ab9)2 goat anti-human IgG and fluorescein isothiocyanate±
conjugated goat anti-mouse immunoglobulin (Sigma). After staining,luminescence (ECL) protein size standards (Amersham). The
proteins were transferred onto nitrocellulose membranes, incubated cells were analyzed on a Becton Dickinson FACScan.
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